Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

NCT07755410 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT07755410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07755410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder
Lead sponsor
Alkermes, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 10, 2026
Completion date
July 31, 2027
Enrollment
312 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit disorder with hyperactivity (adhd)